Menopause · Surgical
Surgical Menopause: What to Expect After Both Ovaries Are Removed
Educational guide · By ClearHormones Editorial Team · Updated July 2026
Surgical menopause is the menopause that begins the moment both ovaries are removed (a bilateral oophorectomy). Unlike natural menopause, which unfolds over years as ovarian function tapers, surgery removes the body's main source of estrogen in a single step. Menopause starts that day, regardless of your age, and the symptoms are often abrupt and intense rather than gradual. It is also permanent: surgical menopause does not reverse, and symptoms that ease over months reflect adaptation, not the ovaries switching back on.
The short answer
The question most people ask right after surgery is whether they need hormone therapy, and for how long. For many people without a medical reason to avoid estrogen, the answer leans toward yes. The 2022 hormone therapy position statement of The North American Menopause Society (NAMS) and the cited surgical-menopause literature discuss that hormone therapy is frequently recommended, absent contraindications, at least until roughly the average age of natural menopause, both to control symptoms and to protect long-term bone and cardiovascular health. That is a decision to make with your own clinician, because the balance depends on why your ovaries were removed and your personal risk profile.
This page explains what changes physically after oophorectomy, why estrogen loss at a younger age carries different stakes than menopause at the typical age, how the main hormone-delivery routes and non-hormonal options compare, and how the cost of treatment is structured so you can have an informed conversation with a provider licensed in your state.
What surgical menopause actually is
Surgical menopause is the immediate loss of ovarian hormone production that follows removal of both ovaries, a procedure called bilateral oophorectomy. The ovaries are the body's principal source of estrogen and a significant source of testosterone, so taking them out ends that supply at once. This is different from a hysterectomy alone: removing the uterus stops periods and pregnancy but, if the ovaries remain, does not by itself cause menopause because the ovaries keep producing hormones.
Because the drop is sudden rather than gradual, the surgical-menopause literature describes symptoms that can be more abrupt and intense than the years-long transition of natural menopause. There is no perimenopause runway. Someone can go into the operating room premenopausal and wake up postmenopausal, which is a physiological and emotional shift worth preparing for before surgery when the timing is planned.
Oophorectomy is done for several reasons — treatment or risk reduction for ovarian or breast cancer, severe endometriosis, or other pelvic disease. The reason matters, because it shapes whether replacing estrogen afterward is appropriate. That is why surgical menopause management is individualized rather than one-size-fits-all.
Why the symptoms hit harder and faster
In natural menopause, described by the Stages of Reproductive Aging Workshop (STRAW+10) framework, hormone levels fluctuate and decline over years, giving the body time to adjust. Surgical menopause compresses that process into a single day. Hot flashes, night sweats, sleep disruption, mood changes, vaginal dryness, and changes in desire can appear quickly and feel more pronounced because there is no gradual taper.
Vasomotor symptoms — hot flashes and night sweats — are among the most commonly reported and are a frequent reason people seek treatment. Genitourinary symptoms such as vaginal dryness and discomfort with sex tend to persist rather than resolve on their own, since they stem from ongoing low estrogen in local tissue. The American College of Obstetricians and Gynecologists (ACOG) notes that changes in desire are multifactorial, involving hormones, sleep, mood, relationships, and health, so they are not always fixed by hormones alone.
Some symptoms ease over months as the body adapts to a new baseline. That improvement is the nervous system recalibrating, not the ovaries resuming function. This is the core point that surprises many people: surgical menopause is permanent, and feeling better later does not mean it reversed.
It is permanent, not temporary
Surgical menopause does not reverse. Once both ovaries are removed, they cannot regenerate hormone production, so menopause is a permanent state. Any improvement in how you feel over the following year reflects adaptation and, where used, treatment — not a return of ovarian function.
This permanence is exactly why the timing horizon matters. If natural menopause would not have arrived for another decade or more, surgery has moved you into an estrogen-deficient state years ahead of schedule. The cited literature associates earlier loss of ovarian hormones — whether premature natural menopause or surgical menopause — with health considerations that accumulate over the added years of deficiency, which is the reasoning behind treating at least until the average age of natural menopause when it is safe to do so.
Understanding this upfront reframes the decision. The question is not usually whether symptoms will pass, but whether to replace the hormones your body would otherwise still be making at your age, and for how long.
Why hormone therapy is often recommended after oophorectomy
For people whose ovaries are removed before the typical age of natural menopause and who have no medical reason to avoid estrogen, hormone therapy is frequently recommended. The NAMS 2022 position statement and the cited surgical-menopause literature frame the goal as replacing hormones the body would normally still produce, rather than adding hormones on top of a normal level. The commonly discussed horizon is continuing at least until roughly the average age of natural menopause, after which the decision is reassessed like any menopausal hormone therapy choice.
The rationale is twofold. First, symptom control: estrogen is the most effective treatment for vasomotor symptoms and helps genitourinary symptoms. Second, long-term health: the extra years of estrogen deficiency created by early oophorectomy are the reason bone and cardiovascular considerations feature so prominently in the guidance. Treating to the average age of natural menopause is, in effect, bringing the estrogen timeline closer to what it would have been.
Contraindications change this calculus. When ovaries are removed as part of treating or reducing the risk of a hormone-sensitive cancer, or when someone has another reason to avoid estrogen, systemic hormone therapy may not be appropriate, and non-hormonal strategies take priority. This is precisely why the choice belongs with a clinician who knows your full history, not a generic rule.
Estrogen with or without a progestogen: the uterus question
A key branch point is whether you still have a uterus. If your uterus was removed at the same time (hysterectomy plus bilateral oophorectomy), systemic estrogen is typically used on its own. If your uterus remains, NAMS 2022 states that a person with a uterus on systemic estrogen needs an adequate progestogen to protect the endometrium (the uterine lining) from the overgrowth that unopposed estrogen can cause.
"Progesterone" refers to the hormone the body makes; FDA-approved micronized progesterone is the bioidentical oral form. "Progestin" or "progestogen" is the umbrella term that also includes synthetic progestins such as medroxyprogesterone, norethindrone, levonorgestrel, and drospirenone. NAMS 2022 indicates that both micronized progesterone and synthetic progestins can provide endometrial protection, and that they differ in side-effect profiles. No single option is universally best; the right one depends on how you tolerate it and your other health factors.
This distinction matters for both effectiveness and comfort. Some people tolerate one form better than another, and the delivery method (oral, or a levonorgestrel intrauterine device in some cases) is part of the conversation. A prescriber weighs these tradeoffs against your history rather than defaulting to one product.
Comparing estrogen delivery routes
Systemic estrogen comes in several forms, and one advantage of having options is flexibility if a particular product is hard to get. If a specific delivery form is unavailable, clinicians can often switch among estradiol routes — patch, gel, spray, oral, or vaginal — which is a decision for the prescriber based on your needs. The table below outlines how the routes differ in practical terms.
Transdermal routes (patch, gel, spray) deliver estradiol through the skin. Oral estrogen is a pill. Low-dose vaginal estrogen is a distinct category aimed mainly at local genitourinary symptoms rather than whole-body symptom control. Availability of specific products can change over time; the FDA Drug Shortages database is the authoritative place to check the current status of any estradiol product before assuming it is or is not in shortage.
| Route | Form | Primary use | Practical notes |
|---|---|---|---|
| Transdermal patch | Adhesive patch changed on a schedule | Whole-body symptom control | Steady delivery; skin-site reactions possible; check FDA database if a product is scarce |
| Transdermal gel or spray | Applied to the skin daily | Whole-body symptom control | Flexible dosing; must dry and avoid transfer to others |
| Oral estradiol | Daily pill | Whole-body symptom control | Simple to take; processed through the liver, which factors into individual risk assessment |
| Vaginal (low-dose) | Cream, tablet, or ring | Local genitourinary symptoms | Targets dryness and discomfort locally; a different goal from systemic therapy |
Bone health after early estrogen loss
Estrogen helps maintain bone density, so losing it early raises the priority of protecting your skeleton. NAMS 2022 addresses bone health in menopause, and the cited surgical-menopause literature is part of why bone protection is emphasized when ovaries are removed before the usual age. Hormone therapy itself supports bone when it is used, which is one of its long-term benefits in this setting.
Nutrition is the foundation. Adequate calcium and vitamin D support bone health, ideally from diet first, with supplementation used when intake is insufficient rather than as a default. Evidence summarized in Maturitas (2020) supports calcium and vitamin D for bone, with discussed roles for vitamin K2 and magnesium. Supplements do not prevent all fractures and do not replace weight-bearing exercise or, where indicated, prescription bone therapy — they are one layer, not the whole plan.
A practical bone plan usually combines several elements: sufficient calcium and vitamin D, regular weight-bearing and resistance exercise, not smoking, moderating alcohol, and bone-density monitoring on a schedule your clinician sets. If testing shows meaningful bone loss, prescription treatments exist and are a separate conversation from supplements. This site does not sell supplements; the point is an evidence-informed framework to discuss with your provider.
Heart and cardiovascular considerations
The cardiovascular angle is one reason the guidance leans toward treating early surgical menopause until around the average age of natural menopause when it is safe. The added years of estrogen deficiency created by early oophorectomy are the backdrop for the long-term health discussion in the cited literature, which is why cardiovascular and bone considerations are weighed alongside symptom relief rather than treated as afterthoughts.
Timing and individual risk drive the benefit-risk balance of hormone therapy, and NAMS 2022 frames the decision around each person's age, time since menopause, and health profile. For someone entering surgical menopause well before the typical age, that framing is different from someone at the usual age, which is a central reason the recommendation is individualized.
Whatever you and your clinician decide about hormones, the general cardiovascular fundamentals still apply: not smoking, staying active, managing blood pressure, cholesterol, and blood sugar, and maintaining a nourishing diet. These support heart health independent of the hormone-therapy decision.
Non-hormonal options and symptom management
When estrogen is not appropriate — for example after a hormone-sensitive cancer — or when someone prefers not to use it, non-hormonal strategies carry more of the load. For hot flashes and night sweats, prescription non-hormonal medications exist and are chosen by a prescriber. Layered clothing, a cool sleep environment, and identifying personal triggers can also help day to day.
Some antidepressants are used for vasomotor symptoms, and it is worth knowing that SSRIs commonly cause sexual side effects, including reduced desire, delayed orgasm, and arousal difficulty. Management strategies exist — adjusting timing, changing agents, or other changes — but they must be done with the prescriber. Never stop an antidepressant abruptly on your own; that is a conversation to have before making any change. Because ACOG notes desire is multifactorial, addressing sleep, mood, and relationship factors matters alongside any medication.
For genitourinary symptoms — dryness, irritation, discomfort with sex — options range from non-hormonal moisturizers and lubricants to low-dose vaginal estrogen, which acts locally. ACOG's sexual-health guidance supports addressing these directly rather than accepting them as unavoidable, and the right combination is individualized.
How the cost of treatment is structured
Hormone therapy pricing is best understood as a set of pathways rather than a single number, and what you pay depends on which pathway applies to you. Generic estradiol products in standard routes are widely available, and many are covered under prescription drug benefits, which usually means a copay tier rather than the full list price. Because formularies and plans differ, the same product can cost different amounts for different people.
When a product is not covered, or you are uninsured, the relevant figure is the cash or list price, which varies by pharmacy and route. Manufacturer savings programs and pharmacy discount options sometimes apply and change the out-of-pocket amount. Compounded hormone preparations — custom-mixed by a compounding pharmacy — are a separate category with their own pricing and are generally not covered the way FDA-approved products are; NAMS and major bodies distinguish FDA-approved products from custom-compounded ones, which is a discussion to have with your clinician. The table maps these pathways so you know which questions to ask.
We do not quote specific dollar amounts because they vary by plan, pharmacy, route, and region, and any single figure would mislead. Ask your pharmacy for the price of the specific product and route your clinician prescribes, both with and without insurance, and ask whether a therapeutically equivalent generic or alternate route lowers the cost.
| Pathway | What it is | How the cost is set | What to ask |
|---|---|---|---|
| Insurance-covered | Product on your plan's formulary | Copay tier, not full list price | Which tier is my product on, and is a lower-tier generic equivalent? |
| Cash / list price | Paying without coverage | Set by pharmacy and route | What is the cash price here versus another pharmacy? |
| Savings / discount programs | Manufacturer or pharmacy discounts | Reduces out-of-pocket where eligible | Is there a savings program for this product? |
| Compounded | Custom-mixed by a compounding pharmacy | Priced by the pharmacy; often not covered like FDA-approved products | Is an FDA-approved product appropriate for me instead? |
How to have the decision conversation with a clinician
Surgical menopause management is a clinician decision because the right plan hinges on details only your medical record holds: why your ovaries were removed, whether you still have a uterus, your bone and cardiovascular risk, and any reason to avoid estrogen. A generic recommendation cannot account for these, which is why this page frames options rather than prescribing an answer.
Useful questions to bring: Given why my ovaries were removed, is systemic hormone therapy appropriate for me, and if so, until roughly what age? If I still have a uterus, what progestogen do you recommend and why? Which estrogen route fits my situation, and what do we do if a product is in short supply? What is my bone-health and cardiovascular plan, with or without hormones? These questions turn a passive appointment into a shared decision.
If you are still choosing a provider, you can compare providers licensed in your state who manage menopause and hormone therapy, and bring this list of questions to the first visit. Prepare before surgery when the timing is planned, so a symptom and treatment plan is ready rather than assembled in a rush afterward.
Frequently asked questions
- Is surgical menopause permanent or does it go away?
- It is permanent. Removing both ovaries ends ovarian hormone production and menopause does not reverse. Symptoms may ease over months as the body adapts and, where used, treatment helps, but that improvement is not the ovaries resuming function.
- Do I need hormone therapy after having both ovaries removed?
- For many people without a medical reason to avoid estrogen, hormone therapy is frequently recommended. NAMS 2022 and the cited literature discuss treating, absent contraindications, at least until roughly the average age of natural menopause for symptom control and long-term bone and cardiovascular health. Because contraindications and personal risk vary, it is a clinician decision.
- Why are surgical menopause symptoms worse than natural menopause?
- Natural menopause unfolds over years, giving the body time to adjust. Surgery removes the ovaries' hormone supply in a single step, so hot flashes, night sweats, sleep disruption, mood changes, and vaginal dryness can appear abruptly and feel more intense because there is no gradual taper.
- If I still have my uterus, do I need progesterone with estrogen?
- Yes. NAMS 2022 states that a person with a uterus on systemic estrogen needs an adequate progestogen to protect the uterine lining. Both micronized progesterone and synthetic progestins can provide protection and differ in side-effect profiles. After a hysterectomy, estrogen is typically used alone. Your prescriber chooses the right option for you.
- What if my estrogen patch is out of stock?
- Availability of specific products can change, and clinicians can often switch among estradiol routes — patch, gel, spray, oral, or vaginal — as a prescriber-led decision. Do not assume a shortage or stockpile; check the FDA Drug Shortages database for the live status of a specific product and talk to your prescriber about alternatives.
- Will calcium supplements protect my bones after surgical menopause?
- Adequate calcium and vitamin D support bone health, ideally from diet first, with supplements used when intake is insufficient. Evidence supports calcium and vitamin D for bone, but supplements do not prevent all fractures and do not replace weight-bearing exercise or, where indicated, prescription bone therapy. They are one layer of a broader plan set with your clinician.
- Can I take hormone therapy if my ovaries were removed for cancer risk?
- Sometimes estrogen is not appropriate, for example when ovaries are removed to treat or reduce the risk of a hormone-sensitive cancer. In those cases non-hormonal strategies take priority. This is exactly why the decision belongs with a clinician who knows your full history rather than a general rule.
- How much does hormone therapy cost?
- Cost depends on the pathway. Many generic estradiol products are covered under prescription benefits as a copay rather than full list price. Without coverage, cash prices vary by pharmacy and route, and savings programs sometimes apply. Compounded preparations are a separate category often not covered like FDA-approved products. Ask your pharmacy for the price of your specific prescription with and without insurance.
Primary sources
- The 2022 hormone therapy position statement of NAMS. Menopause 2022. PMID 35797481.
- Surgical Menopause and Bilateral Oophorectomy: effects. 2022. PMID 36175351.
- Association of Premature Natural and Surgical Menopause with outcomes. 2019. PMID 31738818.
- Stages of Reproductive Aging Workshop +10 (STRAW+10). PMID 22344196.
- Calcium, vitamin D, vitamin K2, and magnesium supplementation and bone health. Maturitas 2020. PMID 32972636.
- ACOG, The Menopause Years.
- ACOG, Your Sexual Health.
- Management strategies in SSRI-associated sexual dysfunction. 2012. PMID 22515703.
- FDA Drug Shortages database.
ClearHormones publishes editorial health information for education only — not medical advice.